Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Probiotic Administration on Mood (PAM)

20 avril 2022 mis à jour par: Lindenwood University

Impact of Probiotic Administration on Mood, Psychological Traits, Physical Activity, Stress, and Sleep Quality

Researchers are looking to examine the impact of probiotic administration on symptoms commonly associated with depression, anxiety, stress, sleep quality, and associated emotional responses in healthy men and women.

Aperçu de l'étude

Statut

Complété

Intervention / Traitement

Description détaillée

In recent years, the presence and awareness of a connection between the intestines and the brain has expanded leading to the understanding of developed communication pathways between the nervous, endocrine, and immune systems. Intestinal bacterial flora are active contributors to this axis through cellular signaling pathways and the release of immune system components, which fundamentally impact the function and action of various physiological systems. Interest in this area evolved through the understanding that various microbiota can produce neuroactive substances and neurotransmitters involved with the endocrine and autonomic nervous system pathways. This research has expanded to state that various bacterial products can influence cognitive functions, involving types of memory and problem-solving. Recent findings have begun to report on the impact that probiotic administration may have on mood, anxiety, and depression. Finally, recent work by Marotta et al. provided some of the first preliminary evidence that probiotic use may also impact mood and sleep quality. While initial work has developed this foundation, very little controlled research is available to help understand key contributing factors. For example, many key questions remain that future research should address to help better understand any impact probiotics may have on mood, depression, and anxiety. Some of these questions include:

Do all forms (genus, strain, etc.) of probiotics exert these impacts? How quickly do they exert impact? How large is the impact? Are certain aspect of affect more impacted than others? Once supplemented, how long is the residual impact (if there is any)? To help provided more guidance towards some of these basic research questions, this study is being proposed. The purpose of the study is to expand upon the previous work of Marotta et al. and determine the impact of probiotic administration on mood, depressive symptoms, anxiety, sleep quality, and other personality traits in a larger group of healthy men and women. This study will expand on the supplementation regimen and include a wider variety of hormonal assessments than what has previously been completed using this combination of probiotics.

Type d'étude

Interventionnel

Inscription (Réel)

70

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Missouri
      • Saint Charles, Missouri, États-Unis, 63301
        • Lindenwood University

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 50 ans (Adulte)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • between the ages of 18 - 50 years
  • has a body mass index between 18.5 - 30 kg/m2.
  • Anyone with a body mass index between 30 - 32 kg/m2, but has a body composition <25% fat -for men and <35% for women will be accepted into the study
  • has been weight stable for the past three months (defined as less than a 5% variation in body -mass over this time)
  • is determined to be healthy through completion of a health history questionnaire

Exclusion Criteria:

  • Are currently diagnosed or being treated for any cardiac, respiratory, endocrine, psychiatric, musculoskeletal, - renal, hepatic, neuromuscular or metabolic disease or disorder that in the judgement of the study participant's personal physician or research nurse that will preclude their safe participation or will contraindicate quality control over the collected data
  • are currently diagnosed with or are being treated for celiac disease, lactose intolerance, digestive insufficiencies or other gastrointestinal complications such as irritable bowel syndrome, ulcerative colitis, etc.
  • report having used anabolic steroids within the past 30 days
  • report have used any illicit or recreational drugs within the past 30 days
  • report the intake of any prescription or over-the-counter medications (i.e., antibiotics) that may impact study outcomes
  • report the current use of any dietary supplements known to impact digestion or sleep quality for the past 30 days
  • report already taking a probiotic within the past 30 days
  • have been actively trying to lose weight
  • are currently following a ketogenic or low carbohydrate diet within the past 30 days

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Autre
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Active Probiotic
A mixture of probiotic strains (2.5 gram daily doses of 4 x 109 CFU/packet) of the following species (Lactobacillus fermentum, Lactobacillus rhamnosus, Lactobacillus plantarum, Bifidobacterium longum).
After baseline or initial testing, participants will be randomly assigned in a double-blind fashion to ingest on a daily basis for 6 weeks either a placebo or a probiotic supplement. Identical follow-up measurements will then occur each visit after taking their assigned supplement. After 6 weeks of administration, the supplementation protocol will stop and a final evaluation will be completed 3 weeks later (9 weeks after initial administration) to assess any residual impact of the assigned supplement after a 3-week washout.
Comparateur placebo: Placebo
Maltodextrin capsule
After baseline or initial testing, participants will be randomly assigned in a double-blind fashion to ingest on a daily basis for 6 weeks either a placebo or a probiotic supplement. Identical follow-up measurements will then occur each visit after taking their assigned supplement. After 6 weeks of administration, the supplementation protocol will stop and a final evaluation will be completed 3 weeks later (9 weeks after initial administration) to assess any residual impact of the assigned supplement after a 3-week washout.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Beck Depression Index II
Délai: 6 Weeks

The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression.

Total Score Levels of Depression 0-10 = These ups and downs are considered normal 11-16 = Mild mood disturbance 17-20 = Borderline clinical depression 21-30 = Moderate depression 31-40 = Severe depression over 40 = Extreme depression

6 Weeks
COPE Inventory
Délai: 6 weeks
The COPE Inventory is a multidimensional coping inventory to assess the different ways in which people respond to stress. Five scales (of four items each) measure conceptually distinct aspects of problem-focused coping (active coping, planning, suppression of competing activities, restraint coping, seeking of instrumental social support); five scales measure aspects of what might be viewed as emotion-focused coping (seeking of emotional social support, positive reinterpretation, acceptance, denial, turning to religion); and three scales measuring coping responses that arguably are less useful (focus on and venting of emotions, behavioral disengagement, mental disengagement).
6 weeks
Leiden Index of Depression Sensitivity - Revised
Délai: 6 weeks
The Leiden Index of Depression Sensitivity (LEIDS) measures cognitive reactivity (CR) to sadness, an aspect of cognitive vulnerability to depression, conceptually similar to rumination. A higher total score on all the subscales except acceptance and coping shows higher CR.
6 weeks
Pittsburgh Sleep Quality Index
Délai: 6 weeks

A self-rated questionnaire to assess sleep quality and disturbances

19 self-reported items Minimum score: 0; Maximum score: 21 Higher scoring indicated worse sleep quality

6 weeks
State-Trait Anxiety Inventory form Y1 and Y2
Délai: 6 weeks
Measure of trait and state anxiety. All items on the scale are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always"). Higher scores indicate greater anxiety. The STAI is appropriate for those who have at least a sixth-grade reading level.
6 weeks
Behavioral Avoidance/Inhibition Scale
Délai: 6 weeks
A measure of motivation to approach goal-oriented outcomes. Higher scores correspond to higher motivation to avoid goal oriented outcomes, lower scores indicate lower motivation to avoid goal-oriented outcomes.
6 weeks
Bowel Health Questionnaire
Délai: 6 weeks
Measure of bowel health. Lower scores indicate lower number of GI disturbances and higher scores indicate higher number of GI disturbances
6 weeks

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Hours Asleep
Délai: 6 weeks
Total hours asleep each night as obtained through a fit bit activity monitor
6 weeks
Minutes Awake
Délai: 6 weeks
Total minutes awake each night as obtained through a fit bit activity monitor
6 weeks
Number of awakenings
Délai: 6 weeks
Number of times awakened each night as obtained through a FitBit activity monitor
6 weeks
Minutes of restlessness
Délai: 6 weeks
Total minutes of restlessness each night as obtained through a FitBit activity monitor
6 weeks
Number of times Restless
Délai: 6 weeks
Number of times restless each night as obtained through a FitBit activity monitor
6 weeks
Total time Awake and Restless
Délai: 6 weeks
Total minutes of time awake and restless each night as obtained through a FitBit activity monitor
6 weeks
Total time in Bed
Délai: 6 weeks
Total time in bed each night as obtained through a FitBit activity monitor
6 weeks
Calories Burned
Délai: 6 weeks
Total KCal burned on average each day as obtained through a FitBit activity monitor
6 weeks
Steps
Délai: 6 weeks
Total number of steps on average each day as obtained through a FitBit activity monitor
6 weeks
Distance
Délai: 6 weeks
Total distance traveled each day on average each day as obtained through a FitBit activity monitor
6 weeks
Minutes Sedentary
Délai: 6 weeks
Total minutes sedentary on average each day as obtained through a FitBit activity monitor
6 weeks
Minutes Lightly Active
Délai: 6 weeks
Total minutes Lightly active on average each day as obtained through a FitBit activity monitor
6 weeks
Minutes Fairly Active
Délai: 6 weeks
Total minutes Fairly active on average each day as obtained through a FitBit activity monitor
6 weeks
Minutes Very Active
Délai: 6 weeks
Total minutes Very active on average each day as obtained through a FitBit activity monitor
6 weeks
Active Calories
Délai: 6 weeks
Total minutes of active calories expended on average each day as obtained through a FitBit activity monitor
6 weeks
Body Composition
Délai: 6 weeks
DEXA derived fat mass and fat free mass and bodyfat percentage
6 weeks

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Collaborateurs

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

17 juillet 2019

Achèvement primaire (Réel)

1 janvier 2022

Achèvement de l'étude (Réel)

1 janvier 2022

Dates d'inscription aux études

Première soumission

29 mars 2022

Première soumission répondant aux critères de contrôle qualité

20 avril 2022

Première publication (Réel)

25 avril 2022

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

25 avril 2022

Dernière mise à jour soumise répondant aux critères de contrôle qualité

20 avril 2022

Dernière vérification

1 avril 2022

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • IRB-19-212

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur Probiotic

3
S'abonner